Understanding the structural dynamics of TCR-pMHC interactions

Trends in Immunology

Volumn 35, Issue 12, 2014, Pages 604-612

  Kass, Itamar ^a   Buckle, Ashley M ^a   Borg, Natalie A ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Conformational flexibility; Molecular dynamics; TCR pMHC interactions

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN; PEPTIDE BOUND MAJOR HISTOCOMPATIBILITY COMPLEX; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

HUMAN; MOLECULAR DYNAMICS; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW;

EID: 84915759725     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2014.10.005     Document Type: Review

References (100)

1. Dustin M.L. Signaling at neuro/immune synapses. J. Clin. Invest. 2012, 122:1149-1155.
2. Chen Y., et al. Structural immunology and crystallography help immunologists see the immune system in action: how T and NK cells touch their ligands. IUBMB Life 2009, 61:579-590.
3. Morikis D., Lambris J.D. Physical methods for structure, dynamics and binding in immunological research. Trends Immunol. 2004, 25:700-707.
4. Garcia K.C., et al. The molecular basis of TCR germline bias for MHC is surprisingly simple. Nat. Immunol. 2009, 10:143-147.
5. Reinherz E.L., et al. The crystal structure of a T cell receptor in complex with peptide and MHC class II. Science 1999, 286:1913-1921.
6. Feng D., et al. Structural evidence for a germline-encoded T cell receptor-major histocompatibility complex interaction 'codon'. Nat. Immunol. 2007, 8:975-983.
7. Dai S., et al. Crossreactive T cells spotlight the germline rules for alphabeta T cell-receptor interactions with MHC molecules. Immunity 2008, 28:324-334.
8. Tynan F.E., et al. A T cell receptor flattens a bulged antigenic peptide presented by a major histocompatibility complex class I molecule. Nat. Immunol. 2007, 8:268-276.
9. Garboczi D.N., et al. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 1996, 384:134-141.
10. Ding Y.H., et al. Two human T cell receptors bind in a similar diagonal mode to the HLA-A2/Tax peptide complex using different TCR amino acids. Immunity 1998, 8:403-411.
11. Madden D.R., et al. The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2. Cell 1993, 75:693-708.
12. Chen J.L., et al. Structural and kinetic basis for heightened immunogenicity of T cell vaccines. J. Exp. Med. 2005, 201:1243-1255.
13. Lee J.K., et al. T cell cross-reactivity and conformational changes during TCR engagement. J. Exp. Med. 2004, 200:1455-1466.
14. Garcia K.C., et al. An alphabeta T cell receptor structure at 2.5 A and its orientation in the TCR-MHC complex. Science 1996, 274:209-219.
15. Scott D.R., et al. Disparate degrees of hypervariable loop flexibility control T-cell receptor cross-reactivity, specificity, and binding mechanism. J. Mol. Biol. 2011, 414:385-400.
16. Borbulevych O.Y., et al. Conformational melding permits a conserved binding geometry in TCR recognition of foreign and self molecular mimics. J. Immunol. 2011, 186:2950-2958.
17. Borbulevych O.Y., et al. T cell receptor cross-reactivity directed by antigen-dependent tuning of peptide-MHC molecular flexibility. Immunity 2009, 31:885-896.
18. Burrows S.R., et al. Hard wiring of T cell receptor specificity for the major histocompatibility complex is underpinned by TCR adaptability. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:10608-10613.
19. Colf L.A., et al. How a single T cell receptor recognizes both self and foreign MHC. Cell 2007, 129:135-146.
20. Hawse W.F., et al. TCR scanning of peptide/MHC through complementary matching of receptor and ligand molecular flexibility. J. Immunol. 2014, 192:2885-2891.
21. Hare B.J., et al. Structure, specificity and CDR mobility of a class II restricted single-chain T-cell receptor. Nat. Struct. Biol. 1999, 6:574-581.
22. Krogsgaard M., et al. Evidence that structural rearrangements and/or flexibility during TCR binding can contribute to T cell activation. Mol. Cell 2003, 12:1367-1378.
23. Huse M., et al. Spatial and temporal dynamics of T cell receptor signaling with a photoactivatable agonist. Immunity 2007, 27:76-88.
24. Hawse W.F., et al. Cutting edge: evidence for a dynamically driven T cell signaling mechanism. J. Immunol. 2012, 188:5819-5823.
25. Faber H.R., Matthews B.W. A mutant T4 lysozyme displays five different crystal conformations. Nature 1990, 348:263-266.
26. Eigenbrot C., et al. Structural effects induced by mutagenesis affected by crystal packing factors: the structure of a 30-51 disulfide mutant of basic pancreatic trypsin inhibitor. Proteins 1992, 14:75-87.
27. Phillips G.N. Comparison of the dynamics of myoglobin in different crystal forms. Biophys. J. 1990, 57:381-383.
28. Fraser J.S., et al. Accessing protein conformational ensembles using room-temperature X-ray crystallography. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:16247-16252.
29. Werlen G., Palmer E. The T-cell receptor signalosome: a dynamic structure with expanding complexity. Curr. Opin. Immunol. 2002, 14:299-305.
30. He H.T., Bongrand P. Membrane dynamics shape TCR-generated signaling. Front. Immunol. 2012, 3:90.
31. Shaw D.E., et al. Atomic-level characterization of the structural dynamics of proteins. Science 2010, 330:341-346.
32. Lindorff-Larsen K., et al. How fast-folding proteins fold. Science 2011, 334:517-520.
33. Kruse A.C., et al. Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature 2012, 482:552-556.
34. Nygaard R., et al. The dynamic process of beta(2)-adrenergic receptor activation. Cell 2013, 152:532-542.
35. Schaeffer R.D., et al. Combining experiment and simulation in protein folding: closing the gap for small model systems. Curr. Opin. Struct. Biol. 2008, 18:4-9.
36. Toh H., et al. Magnitude of structural changes of the T-cell receptor binding regions determine the strength of T-cell antagonism: molecular dynamics simulations of HLA-DR4 (DRB1*0405) complexed with analogue peptide. Protein Eng. 2000, 13:423-429.
37. Toh H., et al. Molecular dynamics simulations of HLA-DR4 (DRB1*0405) complexed with analogue peptide: conformational changes in the putative T-cell receptor binding regions. Protein Eng. 1998, 11:1027-1032.
38. Reboul C.F., et al. Epitope flexibility and dynamic footprint revealed by molecular dynamics of a pMHC-TCR complex. PLoS Comput. Biol. 2012, 8:e1002404.
39. Tynan F.E., et al. High resolution structures of highly bulged viral epitopes bound to major histocompatibility complex class I. Implications for T-cell receptor engagement and T-cell immunodominance. J. Biol. Chem. 2005, 280:23900-23909.
40. Tynan F.E., et al. T cell receptor recognition of a 'super-bulged' major histocompatibility complex class I-bound peptide. Nat. Immunol. 2005, 6:1114-1122.
41. Green K.J., et al. Potent T cell response to a class I-binding 13-mer viral epitope and the influence of HLA micropolymorphism in controlling epitope length. Eur. J. Immunol. 2004, 34:2510-2519.
42. Stavrakoudis A. Insights into the structure of the LC13 TCR/HLA-B8-EBV peptide complex with molecular dynamics simulations. Cell Biochem. Biophys. 2011, 60:283-295.
43. Kjer-Nielsen L., et al. A structural basis for the selection of dominant alphabeta T cell receptors in antiviral immunity. Immunity 2003, 18:53-64.
44. Insaidoo F.K., et al. Loss of T cell antigen recognition arising from changes in peptide and major histocompatibility complex protein flexibility: implications for vaccine design. J. Biol. Chem. 2011, 286:40163-40173.
45. Hawse W.F., et al. Peptide modulation of class I major histocompatibility complex protein molecular flexibility and the implications for immune recognition. J. Biol. Chem. 2013, 288:24372-24381.
46. Fabian H., et al. HLA-B27 heavy chains distinguished by a micropolymorphism exhibit differential flexibility. Arthritis Rheum. 2010, 62:978-987.
47. Fabian H., et al. Influence of inflammation-related changes on conformational characteristics of HLA-B27 subtypes as detected by IR spectroscopy. FEBS J. 2011, 278:1713-1727.
48. Fabian H., et al. HLA-B27 subtypes differentially associated with disease exhibit conformational differences in solution. J. Mol. Biol. 2008, 376:798-810.
49. Pöhlmann T., et al. Differential peptide dynamics is linked to major histocompatibility complex polymorphism. J. Biol. Chem. 2004, 279:28197-28201.
50. Hulsmeyer M., et al. HLA-B27 subtypes differentially associated with disease exhibit subtle structural alterations. J. Biol. Chem. 2002, 277:47844-47853.
51. Hillig R.C., et al. Thermodynamic and structural analysis of peptide- and allele-dependent properties of two HLA-B27 subtypes exhibiting differential disease association. J. Biol. Chem. 2004, 279:652-663.
52. Winkler K., et al. Natural MHC class I polymorphism controls the pathway of peptide dissociation from HLA-B27 complexes. Biophys. J. 2007, 93:2743-2755.
53. Narzi D., et al. Dynamical characterization of two differentially disease associated MHC class I proteins in complex with viral and self-peptides. J. Mol. Biol. 2012, 415:429-442.
54. Lyons D.S., et al. A TCR binds to antagonist ligands with lower affinities and faster dissociation rates than to agonists. Immunity 1996, 5:53-61.
55. van der Merwe P.A., Davis S.J. Molecular interactions mediating T cell antigen recognition. Annu. Rev. Immunol. 2003, 21:659-684.
56. Ding Y.H., et al. Four A6-TCR/peptide/HLA-A2 structures that generate very different T cell signals are nearly identical. Immunity 1999, 11:45-56.
57. Wu L.C., et al. Two-step binding mechanism for T-cell receptor recognition of peptide MHC. Nature 2002, 418:552-556.
58. Willcox B.E., et al. TCR binding to peptide-MHC stabilizes a flexible recognition interface. Immunity 1999, 10:357-365.
59. Koshland D.E. Application of a theory of enzyme specificity to protein synthesis. Proc. Natl. Acad. Sci. U.S.A. 1958, 44:98-104.
60. Armstrong K.M., et al. Conformational changes and flexibility in T-cell receptor recognition of peptide-MHC complexes. Biochem. J. 2008, 415:183-196.
61. Armstrong K.M., Baker B.M. A comprehensive calorimetric investigation of an entropically driven T cell receptor-peptide/major histocompatibility complex interaction. Biophys. J. 2007, 93:597-609.
62. Boehr D.D., et al. The role of dynamic conformational ensembles in biomolecular recognition. Nat. Chem. Biol. 2009, 5:789-796.
63. Csermely P., et al. Induced fit, conformational selection and independent dynamic segments: an extended view of binding events. Trends Biochem. Sci. 2010, 35:539-546.
64. Wolfson M.Y., et al. The effect of mutations on the alloreactive T cell receptor/peptide-MHC interface structure: a molecular dynamics study. J. Phys. Chem. B 2011, 115:8317-8327.
65. Felix N.J., et al. Alloreactive T cells respond specifically to multiple distinct peptide-MHC complexes. Nat. Immunol. 2007, 8:388-397.
66. Stavrakoudis A. Cis-trans isomerization of the Epstein-Barr virus determinant peptide EENLLDFVRF after the DM1 TCR recognition of the HLA-B*4405/peptide complex. FEBS Lett. 2011, 585:485-491.
67. Cuendet M.A., et al. How T cell receptors interact with peptide-MHCs: a multiple steered molecular dynamics study. Proteins 2011, 79:3007-3024.
68. Boniface J.J., et al. Thermodynamics of T cell receptor binding to peptide-MHC: evidence for a general mechanism of molecular scanning. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:11446-11451.
69. Stewart-Jones G.B., et al. A structural basis for immunodominant human T cell receptor recognition. Nat. Immunol. 2003, 4:657-663.
70. Ishizuka J., et al. The structural dynamics and energetics of an immunodominant T cell receptor are programmed by its Vbeta domain. Immunity 2008, 28:171-182.
71. Arumugam S., et al. Increased backbone mobility in beta-barrel enhances entropy gain driving binding of N-TIMP-1 to MMP-3. J. Mol. Biol. 2003, 327:719-734.
72. Yu L., et al. Backbone dynamics of the C-terminal domain of Escherichia coli topoisomerase I in the absence and presence of single-stranded DNA. Biochemistry 1996, 35:9661-9666.
73. Mukherjee P., et al. Picosecond dynamics of a membrane protein revealed by 2D IR. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:3528-3533.
74. Wan S., et al. Toward an atomistic understanding of the immune synapse: large-scale molecular dynamics simulation of a membrane-embedded TCR-pMHC-CD4 complex. Mol. Immunol. 2008, 45:1221-1230.
75. Bello M., Correa-Basurto J. Molecular dynamics simulations to provide insights into epitopes coupled to the soluble and membrane-bound MHC-II complexes. PloS ONE 2013, 8:e72575.
76. Irvine D.J., et al. Direct observation of ligand recognition by T cells. Nature 2002, 419:845-849.
77. Marrink S.J., et al. The MARTINI force field: coarse grained model for biomolecular simulations. J. Phys. Chem. B 2007, 111:7812-7824.
78. Franco-Gonzalez J.F., et al. Exploring the dynamics and interaction of a full ErbB2 receptor and Trastuzumab-Fab antibody in a lipid bilayer model using Martini coarse-grained force field. J. Comput. Aided Mol. Des. 2014, Published online August 17, 2014 http://dx.doi.org/10.1007/s10822-014-9787-2.
79. Bharadwaj M., et al. Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. Annu. Rev. Pharmacol. Toxicol. 2012, 52:401-431.
80. Daly A.K., et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet. 2009, 41:816-819.
81. Mallal S., et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002, 359:727-732.
82. Illing P.T., et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 2012, 486:554-558.
83. Ostrov D.A., et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:9959-9964.
84. Scott D.R., et al. Limitations of time-resolved fluorescence suggested by molecular simulations: assessing the dynamics of T cell receptor binding loops. Biophys. J. 2012, 103:2532-2540.
85. Mage M.G., et al. The peptide-receptive transition state of MHC class I molecules: insight from structure and molecular dynamics. J. Immunol. 2012, 189:1391-1399.
86. Grakoui A., et al. The immunological synapse: a molecular machine controlling T cell activation. Science 1999, 285:221-227.
87. Kohlhoff K.J., et al. Cloud-based simulations on Google Exacycle reveal ligand modulation of GPCR activation pathways. Nat. Chem. 2014, 6:15-21.
88. Dror R.O., et al. Pathway and mechanism of drug binding to G-protein-coupled receptors. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:13118-13123.
89. Pande V.S., et al. Everything you wanted to know about Markov State Models but were afraid to ask. Methods 2010, 52:99-105.
90. Shirts M., Pande V.S. COMPUTING: Screen Savers of the World Unite!. Science 2000, 290:1903-1904.
91. Sugita Y., Okamoto Y. Replica-exchange molecular dynamics method for protein folding. Chem. Phys. Lett. 1999, 314:141-151.
92. Patriksson A., van der Spoel D. A temperature predictor for parallel tempering simulations. Phys. Chem. Chem. Phys. 2008, 10:2073-2077.
93. Hess B., et al. GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation. J. Chem. Theor. Comput. 2008, 4:435-447.
94. Friedrichs M.S., et al. Accelerating molecular dynamic simulation on graphics processing units. J. Comput. Chem. 2009, 30:864-872.
95. Suhartanto H., et al. Performance analysis cluster and GPU computing environment on molecular dynamic simulation of BRV-1 and REM2 with GROMACS. Int. J. Comput. Sci. Issues 2012, 8:131-135.
96. Dror R.O., et al. Anton, a special-purpose molecular simulation machine. Encyclopedia of Parallel Computing 2011, 60-71. Springer, US. D. Padua (Ed.).
97. Hess B. P-LINCS: a parallel linear constraint solver for molecular simulation. J. Chem. Theor. Comput. 2007, 4:116-122.
98. Rognan D., et al. Molecular dynamics study of a complex between the human histocompatibility antigen HLA-A2 and the IMP58-66 nonapeptide from influenza virus matrix protein. Eur. J. Biochem. 1992, 208:101-113.
99. Cuendet M.A., Michielin O. Protein-protein interaction investigated by steered molecular dynamics: the TCR-pMHC complex. Biophys. J. 2008, 95:3575-3590.
100. Knapp B., et al. Large scale characterization of the LC13 TCR and HLA-B8 structural landscape in reaction to 172 altered peptide ligands: a molecular dynamics simulation study. PLoS Comput. Biol. 2014, 10:e1003748.